Globus Medical reported second quarter 2026 worldwide net sales of $789.6 million, up 5.9% year-over-year, or 5.6% on a constant currency basis. GAAP diluted earnings per share fell 26.2% to $1.10, primarily due to a $110.5 million bargain purchase gain from the Nevro acquisition in the prior year quarter. However, non-GAAP diluted EPS rose 55.8% to $1.34. US spine sales grew 7%, whilst international spine sales increased 14% as-reported and 12% on a constant currency basis. Excluding Nevro, overall revenue growth was 9%. The musculoskeletal technology company reaffirmed full-year 2026 revenue guidance of $3.18 billion to $3.22 billion. It raised its non-GAAP fully diluted EPS guidance to $4.95 to $5.05 from the previous range of $4.70 to $4.80.

Globus Medical reported strong first-quarter 2026 results, with revenue climbing 27% year-over-year to nearly $760 million and earnings per share rising to $1.12 from 68 cents, both exceeding analyst expectations. The $11 billion medical device company, which designs implantable devices and surgical instruments for spinal disorders, attributes growth to expanding market share, operational discipline, and dozens of new product launches. The company's US business has posted three consecutive quarters of at least 10% growth, whilst its international segment and enabling technologies division are also expanding. Following the strong performance, Globus raised its full-year EPS guidance by 30 cents to a range of $4.70-$4.80. The firm continues receiving FDA clearances to expand its product lineup.

Globus Medical shares rose 5.1% to $79.23 following strong first-quarter 2026 results. The medical device company posted adjusted earnings per share of $1.12 and revenues of $759.9 million, both exceeding Zacks Consensus Estimates. The company is expected to report quarterly earnings of $1.12 per share in its upcoming report, representing a 30.2% year-on-year increase. Revenues are forecast at $787.34 million, up 5.6% from the previous year. The consensus EPS estimate has been revised 2.5% higher over the past 30 days. Globus Medical currently carries a Zacks Rank #2 (Buy). The stock has declined 10.3% over the past four weeks despite the recent surge.